The Universal Character of the Tumor-Associated Antigen Survivin

Survivin is expressed in most human neoplasms, but is absent in normal, differentiated tissues. Survivin is a bifunctional inhibitor of apoptosis protein that has been implicated in protection from apoptosis and regulation of mitosis. Several clinical trials targeting survivin with a collection of d...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2007-10, Vol.13 (20), p.5991-5994
Main Authors: HALD ANDERSEN, Mads, MARIE SVANE, Inge, BECKER, Jurgen C, THOR STRATEN, Per
Format: Article
Language:English
Subjects:
Animals
Antigens, Neoplasm - chemistry
Antineoplastic agents
Antineoplastic Agents - pharmacology
Apoptosis
Biological and medical sciences
Cancer vaccines
Clinical Trials as Topic
Down-Regulation
Gene Expression Regulation, Neoplastic
Humans
Immune responses to cancer
Immunotherapy - methods
Inhibitor of Apoptosis Proteins
Medical sciences
Microtubule-Associated Proteins - metabolism
Microtubule-Associated Proteins - physiology
Models, Biological
Neoplasm Proteins - metabolism
Neoplasm Proteins - physiology
Neoplasms - metabolism
New targets
Pharmacology. Drug treatments
Protein Biosynthesis
Survival factors
Survivin
T-Lymphocytes, Cytotoxic - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Survivin is expressed in most human neoplasms, but is absent in normal, differentiated tissues. Survivin is a bifunctional inhibitor of apoptosis protein that has been implicated in protection from apoptosis and regulation of mitosis. Several clinical trials targeting survivin with a collection of different approaches from small molecule antagonists to immunotherapy are currently under way. With regard to the latter, spontaneous anti-survivin T-cell reactivity has been described in cancer patients suffering from a huge range of cancers of different origin, e.g., breast and colon cancer, lymphoma, leukemia, and melanoma. Thus, survivin may serve as a universal target antigen for anticancer immunotherapy. Accordingly, down-regulation of survivin as a means of immune escape would severely inflict the survival capacity of tumor cells, which highlights this protein as a prime target candidate for therapeutic vaccinations against cancer. Data from several ongoing phase I/II trials targeting survivin for patients with advanced cancer will provide further information about this idea.
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-07-0686